Jiewen Peng

551 total citations
19 papers, 331 citations indexed

About

Jiewen Peng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Jiewen Peng has authored 19 papers receiving a total of 331 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Epidemiology. Recurrent topics in Jiewen Peng's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Inflammatory Biomarkers in Disease Prognosis (4 papers). Jiewen Peng is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Inflammatory Biomarkers in Disease Prognosis (4 papers). Jiewen Peng collaborates with scholars based in China. Jiewen Peng's co-authors include Gui‐Nan Lin, Zhongjun Xia, Dongying Liu, Xiaoqin Chen, Panpan Liu, Mei Li, Jianjun Xiao, Changxuan You, Fenlai Tan and Li Zhang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Journal of Agricultural and Food Chemistry.

In The Last Decade

Jiewen Peng

18 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiewen Peng China 10 206 103 73 59 53 19 331
Gui‐Nan Lin China 8 254 1.2× 97 0.9× 55 0.8× 135 2.3× 32 0.6× 9 359
Xiao Hu China 9 127 0.6× 118 1.1× 40 0.5× 58 1.0× 77 1.5× 33 267
Jian‐Guo Hong China 11 158 0.8× 45 0.4× 93 1.3× 49 0.8× 52 1.0× 30 315
Kunli Zhu China 13 233 1.1× 97 0.9× 80 1.1× 45 0.8× 55 1.0× 28 342
W. Brückl Germany 10 198 1.0× 163 1.6× 45 0.6× 45 0.8× 52 1.0× 27 329
Brice Chanez France 11 139 0.7× 74 0.7× 41 0.6× 35 0.6× 51 1.0× 31 258
Longgang Cui China 7 297 1.4× 159 1.5× 26 0.4× 72 1.2× 61 1.2× 17 383
Yi-Hong Ling China 10 123 0.6× 120 1.2× 39 0.5× 62 1.1× 87 1.6× 12 333
Marie-Léa Gauci France 8 257 1.2× 57 0.6× 67 0.9× 18 0.3× 47 0.9× 12 342

Countries citing papers authored by Jiewen Peng

Since Specialization
Citations

This map shows the geographic impact of Jiewen Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiewen Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiewen Peng more than expected).

Fields of papers citing papers by Jiewen Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiewen Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiewen Peng. The network helps show where Jiewen Peng may publish in the future.

Co-authorship network of co-authors of Jiewen Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Jiewen Peng. A scholar is included among the top collaborators of Jiewen Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiewen Peng. Jiewen Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chen, Jianwen, et al.. (2025). Icariin Supplementation Alleviates Cognitive Impairment Induced by d-Galactose via Modulation of the Gut–Brain Axis. Journal of Agricultural and Food Chemistry. 73(24). 15138–15154.
2.
Peng, Jiewen, et al.. (2022). LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway. PLoS ONE. 17(2). e0263997–e0263997. 19 indexed citations
3.
Peng, Jiewen, et al.. (2022). [China guideline for the screening and early detection of prostate cancer (2022, Beijing)].. PubMed. 44(1). 29–53. 14 indexed citations
4.
Xu, Wei, Gui‐Nan Lin, Min Wu, et al.. (2021). Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report. Thoracic Cancer. 12(8). 1256–1259. 5 indexed citations
5.
Hong, Shaodong, Yan Huang, Yunpeng Yang, et al.. (2020). GEM20110714: Final overall survival results of the phase III study of first-line gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.. Journal of Clinical Oncology. 38(15_suppl). 6521–6521. 3 indexed citations
6.
7.
Peng, Jiewen, et al.. (2018). Successful treatment of metastatic extramammary Paget's disease with pemetrexed monotherapy systemically and 5-fluorouracil topically. Indian Journal of Dermatology Venereology and Leprology. 85(1). 56–56. 4 indexed citations
8.
Xue, Cong, Shaodong Hong, Ning Li, et al.. (2015). Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment. Scientific Reports. 5(1). 10648–10648. 8 indexed citations
9.
Peng, Jiewen, et al.. (2015). Hepatitis B Virus Infection Is Associated with Poor Prognosis in Patients with Advanced Non Small Cell Lung Cancer. Asian Pacific Journal of Cancer Prevention. 16(13). 5285–5288. 15 indexed citations
10.
11.
Hu, Xingsheng, Baohui Han, Aiqin Gu, et al.. (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer. 86(2). 207–212. 31 indexed citations
12.
Lin, Gui‐Nan, Xiaomei Jiang, Jiewen Peng, et al.. (2014). Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy. Asian Pacific Journal of Cancer Prevention. 15(15). 6387–6390. 8 indexed citations
13.
14.
15.
16.
17.
Tan, Fenlai, Aiqin Gu, Yiping Zhang, et al.. (2013). Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.. Journal of Clinical Oncology. 31(15_suppl). e19161–e19161. 3 indexed citations
18.
19.
Peng, Jiewen, et al.. (1996). [Co-regulative effect of PKA-RII and PKC-alpha kinase subspecies on expression of c-myc and c-H-ras in human gastric cancer cells (MGC 80-3)].. PubMed. 29(3). 197–205. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gui‐Nan Lin Breakdown of academic impact, for papers by Xiao Hu Breakdown of academic impact, for papers by Jian‐Guo Hong Breakdown of academic impact, for papers by Kunli Zhu Breakdown of academic impact, for papers by W. Brückl Breakdown of academic impact, for papers by Brice Chanez Breakdown of academic impact, for papers by Longgang Cui Breakdown of academic impact, for papers by Yi-Hong Ling Breakdown of academic impact, for papers by Marie-Léa Gauci
Rankless by CCL
2026